Licenses and Exclusivity. 5.1 Licenses from Aarvik to ArriVent. Aarvik hereby grants to ArriVent, effective as of the date on which ArriVent exercises the Option, an exclusive (even as to Aarvik), sub-licensable license under the Aarvik IP for the Research, Development, Manufacture, use, Commercialization or other Exploitation of the ADCs related to the Target Pair in the Field in the Territory. Such license shall apply to no other use or purpose by ArriVent or its Sublicensees. Notwithstanding anything in this Agreement to the contrary, but subject to the restrictions set forth in Section 5.4 below, Aarvik shall be entitled to freely use all payloads and linker-payloads utilized in connection with the Products for any and all other purposes.
Licenses and Exclusivity. All licenses granted in Article 7 with respect to such Program will terminate; provided that such licenses will continue as necessary for the Parties to complete the orderly wind-down of their activities under this Agreement in accordance with Applicable Law and as otherwise required in accordance with Section 13.5(a)(ii). With the exception of such wind-down activities, Ipsen shall immediately [***]. The exclusivity obligations set forth in Section 7.5 with respect to such Program will also terminate.
Licenses and Exclusivity. 7.1 License to AZ under Rigel Technology.
Licenses and Exclusivity. 3.1 Survival and Amendment of License Grants to AbbVie.
(a) Product Licenses under the License Agreement. The licenses granted by Reata to AbbVie under Section 5.1.1, Section 5.1.2 and Section 5.1.3 (and all other sections cross-referenced, and defined terms used in such Sections) of the License Agreement expressly survive the termination of the License Agreement under Section 2.1, provided that they are amended to be fully-paid and irrevocable and they shall otherwise continue in full force and effect in perpetuity, unless and until the Bardoxolone Reversion Date occurs (as amended, the “Product Licenses”). For clarity, the licenses and rights granted under Sections 5.1.4, 5.1.5, and 5.1.6 of the License Agreement shall terminate and be of no further force and effect as of the A&R Date and accordingly, all rights referenced therein shall, as of the A&R Date, revert to Reata.
(b) Collaboration Licenses under the Collaboration Agreement. The licenses granted by Reata to AbbVie under Section 10.1(a)(i) and Section 10.1(a)(iii) (and all other sections cross-referenced, and defined terms used in such Sections) of the Collaboration Agreement expressly survive the termination of the Collaboration Agreement under Section 2.1; provided that they are amended to be fully-paid and irrevocable and they shall otherwise continue in full force and effect in perpetuity, unless and until the Omaveloxolone Reversion Date occurs (as amended, the “Collaboration Licenses”). For clarity, the licenses and rights granted under Sections 10.1(a)(ii), and Sections 10.1(a)(iv) though (vi) of the Collaboration Agreement shall terminate and be of no further force and effect as of the A&R Date and accordingly, all rights referenced therein shall, as of the A&R Date, revert to Reata.
Licenses and Exclusivity. 2.1 License to Alaunos for Licensed Products.
Licenses and Exclusivity. 2.1 License to Jazz for HemOnc Products.
Licenses and Exclusivity. 2.1 Licenses to Takeda under AMAG Technology
Licenses and Exclusivity. 1Licenses from Aarvik to ArriVent; Restriction.
Licenses and Exclusivity. 7.1 ImmunoGen Grants
7.2 Aventis Grants
7.3 Technology Transfer
7.4 Retained Rights
7.5 Exclusivity
7.6 Section 365(n) of the Bankruptcy Code
Licenses and Exclusivity. All licenses granted in Article 4 shall terminate and the exclusivity obligations set forth in Section 4.4 shall terminate;